Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer
A Phase 1b and Pharmacodynamic Study of Nintedanib Monotherapy for Advanced Pancreatic Cancer
Sponsor: Boehringer Ingelheim
Terminated
The study was terminated due to futility and lack of future funding
Listed as NCT02902484, this PHASE1/PHASE2 trial focuses on Cancer of Pancreas and remains terminated or withdrawn. Sponsored by Boehringer Ingelheim, it has been updated 13 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Status: Active Not Recruiting → Terminated · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Sep 2022 — Oct 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2021 — Sep 2022 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 8 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2020 — Oct 2020 [monthly]
Recruiting PHASE1_PHASE2
-
May 2019 — Feb 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — May 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2017 — Mar 2018 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
- South Plains Oncology Consortium
- The University of Texas Health Science Center at San Antonio
- University of Texas Southwestern Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .